1. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
- Author
-
Drew W. Rasco, Vincent Chung, Mark Voskoboynik, Talia Golan, Mallika Lala, Myung-Ju Ahn, J. Healy, Dai Woo Kim, Elliot Chartash, Corinne Maurice-Dror, Todd M. Bauer, Dongwhane Lee, Adnan Nagrial, Ulka N. Vaishampayan, Jiaxin Niu, Q. Chen, H.C. Chung, K.F. Mileham, and Antonio Jimeno
- Subjects
medicine.medical_specialty ,Lung Neoplasms ,Combination therapy ,business.industry ,Hematology ,Pembrolizumab ,Antibodies, Monoclonal, Humanized ,medicine.disease ,Gastroenterology ,Rash ,B7-H1 Antigen ,Oncology ,Tolerability ,Pharmacokinetics ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Humans ,Hypoalbuminemia ,medicine.symptom ,Lung cancer ,Adverse effect ,business ,Response Evaluation Criteria in Solid Tumors - Abstract
In this first-in-human phase 1 study (NCT02964013; MK-7684-001), we investigated the safety and efficacy of the anti-TIGIT (T cell immunoglobulin and ITIM domain) antibody vibostolimab as monotherapy or in combination with pembrolizumab.Part A enrolled patients with advanced solid tumors, and part B enrolled patients with non-small-cell lung cancer (NSCLC). Patients received vibostolimab 2.1-700 mg alone or with pembrolizumab 200 mg in part A and vibostolimab 200 mg alone or with pembrolizumab 200 mg in part B. Primary endpoints were safety and tolerability. Secondary endpoints included pharmacokinetics and objective response rate (ORR) per RECIST v1.1.Part A enrolled 76 patients (monotherapy, 34; combination therapy, 42). No dose-limiting toxicities were reported. Across doses, 56% of patients receiving monotherapy and 62% receiving combination therapy had treatment-related adverse events (TRAEs); grade 3-4 TRAEs occurred in 9% and 17% of patients, respectively. The most common TRAEs were fatigue (15%) and pruritus (15%) with monotherapy and pruritus (17%) and rash (14%) with combination therapy. Confirmed ORR was 0% with monotherapy and 7% with combination therapy. In part B, 39 patients had anti-PD-1 (programmed cell death protein 1)/PD-L1 (programmed death-ligand 1)-naive NSCLC (all received combination therapy), and 67 had anti-PD-1/PD-L1-refractory NSCLC (monotherapy, 34; combination therapy, 33). In patients with anti-PD-1/PD-L1-naive NSCLC: 85% had TRAEs-the most common were pruritus (38%) and hypoalbuminemia (31%); confirmed ORR was 26%, with responses occurring in both PD-L1-positive and PD-L1-negative tumors. In patients with anti-PD-1/PD-L1-refractory NSCLC: 56% receiving monotherapy and 70% receiving combination therapy had TRAEs-the most common were rash and fatigue (21% each) with monotherapy and pruritus (36%) and fatigue (24%) with combination therapy; confirmed ORR was 3% with monotherapy and 3% with combination therapy.Vibostolimab plus pembrolizumab was well tolerated and demonstrated antitumor activity in patients with advanced solid tumors, including patients with advanced NSCLC.
- Published
- 2022
- Full Text
- View/download PDF